---
document_datetime: 2025-12-19 16:38:50
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/avastin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: avastin-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.1847377
conversion_datetime: 2025-12-23 04:41:49.240787
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Avastin

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number         | Scope   | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|----------------------------|---------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| PSUR / EMA/PSUR/0000274402 | - -     | 16/10/2025                          | 18/12/2025                                  | SmPC                             | Variation |

1  Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.

2  A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.

3  SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                                       | In view of available data on hyaline occlusive glomerular microangiopathy reported in the literature, including in some cases a positive de-challenge and in view of a plausible mechanism of action, the PRAC considers a causal relationship between bevacizumab and hyaline occlusive glomerular microangiopathy is at least a reasonable possibility. The PRAC concluded that the product information of products containing bevacizumab should be amended accordingly.   |            |            |                        |                                                                                                                                                                                                                                                              |
|---------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IB / EMA/VR/0000295046 | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.k New storage site of Master Cell Bank and/or Working Cell Banks - Accepted                                                   | 14/10/2025 | N/A        |                        |                                                                                                                                                                                                                                                              |
| Variation type IB / EMA/VR/0000263392 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Other variation - Accepted C.I.z - to update SmPC section 2, 4,4 and 6,1 to include information on excipient content (Polysorbate 20), according to the                                                                                                                                                                                                                                                                   | 25/04/2025 | 18/12/2025 | SmPC, Labelling and PL | To update SmPC section 2, 4,4 and 6,1 to include information on excipient content (Polysorbate 20), according to the Excipients guidance. The package leaflet is updated accordingly. In addition, the MAH has taken the opportunity to make minor editorial |

<div style=\"page-break-after: always\"></div>

|                                       | Excipients guidance. The package leaflet is updated accordingly. In addition, the MAH has taken the opportunity to make minor editorial corrections throughout the annexes. In addition, the MAH took the opportunity to update the details of the local representatives in BE, LU, MT.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |            |            |                                  | corrections throughout the annexes.   |
|---------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|---------------------------------------|
| Variation type IB / EMA/VR/0000245353 | This was an application for a group of variations. B.I.a.2 Changes in the manufacturing process of the active substance - B.I.a.2.a Minor change in the manufacturing process of the active substance - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a | 21/02/2025 | 18/12/2025 | SmPC, Annex II, Labelling and PL |                                       |

<div style=\"page-break-after: always\"></div>

| quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted A.5 Change in the name and/or address of a manufacturer/importer of the finished product (including batch release or quality control testing sites) - A.5.b The activities for which the manufacturer/importer is responsible do not include batch release - Accepted   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|